# US 11,992,563 B2 · Composite material for rapid blood clotting and preparation method thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,992,563 B2
- Document ID: US11992563B2
- Status: Granted
- Kind: B2
- Application number: 18/341,748
- Filed: 2023-06-26
- Published: 2023-10-26
- Granted: 2024-05-28
- Earliest claimed: 2021-10-22
- Assignees: Guangdong Ocean University
- Applicants: Guangdong Ocean University
- Inventors: Zhang Hu; Lefan Li; Yu Cheng; Mingneng Liao
- Web page: https://patentgrep.com/patent/US11992563B2

## CPC

- A61L 15/28: Polysaccharides or their derivatives {(A61L15/225 takes precedence)}
- A61L 15/42: Use of materials characterised by their function or physical properties (liquid bandages A61L26/00)
- A61L 15/18: containing inorganic materials
- A61L 15/20: containing organic materials
- A61L 24/0073: {with a macromolecular matrix}
- A61L 24/0089: {containing inorganic fillers not covered by groups A61L24/0078 or A61L24/0084}
- C08B 37/003: {Chitin, i.e. 2-acetamido-2-deoxy-(beta-1,4)-D-glucan or N-acetyl-beta-1,4-D-glucosamine; Chitosan, i.e. deacetylated product of chitin or (beta-1,4)-D-glucosamine; Derivatives thereof}
- A61L 2300/102: Metals or metal compounds, e.g. salts such as bicarbonates, carbonates, oxides, zeolites, silicates
- A61L 2300/418: Agents promoting blood coagulation, blood-clotting agents, embolising agents
- A61L 2400/04: Materials for stopping bleeding
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)
- C08B: POLYSACCHARIDES; DERIVATIVES THEREOF (polysaccharides containing less than six saccharide radicals attached to each other by glycosidic linkages C07H; fermentation or enzyme-using processes C12P19/00; sugar industry C13; production of cellulose D21)

## Abstract

A composite material for rapid blood clotting and its preparation method are provided. The composite material includes the following raw materials in parts by weight: 8˜20 parts of chitosan, 7˜14 parts of salicylaldehyde, 8˜16 parts of 2-aminoisonicotinic acid, 1.5˜3.5 parts of ferrous sulfate, 3˜5 parts of dopa, and 10˜15 parts of disodium hydrogen phosphate. The composite material for rapid blood clotting has good stability, high biological safety, significant effects on blood clotting, simple process, and easy industrial production.

## Claims

### Claim 1

A composite material for blood clotting, wherein the composite material is formed by using the following raw materials in parts by weight: 8 to 20 parts of chitosan, 7 to 14 parts of salicylaldehyde, 8 to 16 parts of 2-aminoisonicotinic acid, 1.5 to 3.5 parts of ferrous sulfate (Fe2+ sulphate), 3 to 5 parts of a dopa compound, and 10 to 15 parts of disodium hydrogen phosphate;
wherein a chitosan-based Fe2+ complex is formed by introducing the 2-aminoisonicotinic acid onto a molecular chain of the chitosan through an acylation reaction to obtain chitosan-amino isonicotinic acid graft, forming a Schiff base by condensation of the salicylaldehyde and amino groups of the 2-aminoisonicotinic acid, and combining the Schiff base with the ferrous sulfate;
wherein the composite material comprises: a charge transfer compound formed according to the dopa ingredient and the chitosan-based Fe2+ complex;
wherein the composite material has a porous structure formed by interacting hydrogen phosphate anions of the disodium hydrogen phosphate with protonated amino groups of the chitosan to generate electrostatic and hydrogen bond effects;
wherein the composite material is in a form of solid; and the composite material forms a hydrogel after absorbing liquid;
a molecular mass of the chitosan is 50˜300 kilodaltons (KDa), and a degree of deacetylation of the chitosan is 80˜95%.

### Claim 2 (depends on 1)

The composite material for blood clotting according to claim 1, wherein the raw materials are, in parts by weight, as follows: 14 parts of the chitosan, 10 parts of the salicylaldehyde, 12 parts of the 2-aminoisonicotinic acid, 2.5 parts of the ferrous sulfate, 4 parts of the dopa, and 13 parts of the disodium hydrogen phosphate.

### Claim 3 (depends on 1)

The composite material for blood clotting according to claim 1, wherein the molecular mass of the chitosan is 100 KDa, and the degree of deacetylation of the chitosan is 90%.

### Claim 4 (depends on 1)

The composite material for blood clotting according to claim 1, wherein the chitosan is 140 g, the salicylaldehyde is 100 g, the 2-aminoisonicotinic acid is 120 g, the ferrous sulfate is 25 g, the dopa is 40 g and the disodium hydrogen phosphate is 130 g.